RareResearch.AI
← Back to atlas

W371*

NonsenseN1PathogenicTransmembrane · predicted
Nonsense variant · truncation point at position 371 · Transmembrane helix 3 · WFS1 (Wolframin)

N1NMD-targeted — null allele

Wild-type vs Translated Product

Wild-type · full length
Full wild-type wolframin · 890 aa — truncation point at residue 371
Fullscreen ↗
Translated product
Native sequence to residue 370; everything highlighted (residues 371–890) is lost
Fullscreen ↗

Left: full-length wild-type wolframin (890 aa) with the truncation point at residue 371 marked. Right: the same model with the lost region (residues 371–890) marked — what the nonsense transcript fails to produce as native protein.

Structural / NMD Prediction

Variant type
Nonsense
NMD status
NMD-targeted
high confidence
Schema
N1
NMD-targeted — null allele
Native protein retained
41.6%

Stop codon at position 371 is more than 50 nt upstream of the last exon-exon junction (~aa 413). The 50-nt rule predicts the transcript is degraded by nonsense-mediated decay. No truncated protein is produced; functionally a null allele.

Therapeutic Implication · N1

Transcript degraded by NMD; no truncated protein produced. Therapeutic options: (a) translational readthrough drugs — Ataluren/PTC124, gentamicin-class aminoglycosides — may rescue partial readthrough; (b) gene therapy — allele replacement is the higher-yield long-term path. Pharmacological chaperones do not apply since no protein is made.

Protein Domains

Retained (aa 1–370)
  • N-terminal cytoplasmic (intrinsically disordered)1310
  • Transmembrane helix 1311331
  • Cytoplasmic loop 1332340
  • Transmembrane helix 2341361
  • Lumenal loop 1362370
Lost / non-native (downstream)
  • Transmembrane helix 3371391
  • Cytoplasmic loop 2392400
  • Transmembrane helix 4401421
  • Lumenal loop 2422431
  • Transmembrane helix 5432452
  • Cytoplasmic loop 3453461
  • Transmembrane helix 6462482
  • Lumenal loop 3483496
  • Transmembrane helix 7497517
  • Cytoplasmic loop 4518532
  • Transmembrane helix 8533553
  • Lumenal loop 4554573
  • Transmembrane helix 9574594
  • Cytoplasmic loop 5 / pre-lumenal595599
  • C-terminal ER-lumenal (calcium binding, calmodulin, chaperone)600890

Clinical Evidence

ClinVar classificationPathogenic
Review statuscriteria provided, single submitter
Associated conditionsWolfram syndrome 1
Population frequency (gnomAD v4)Ultra-rare · AF 0.00027%
cDNA changec.1112G>A
ClinVar variantNM_006005.3(WFS1):c.1112G>A (p.Trp371Ter)
ClinVar accessionVCV001709531
Last evaluated2022/07/19 00:00

Observed at very low frequency in gnomAD.

Classified for1★ unverified submission

ClinVar classifies this variant as Pathogenic for Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). Classic Wolfram syndrome is recessive: a single copy does not produce it, and this classification says nothing about a carrier's own risk.

  • Wolfram syndrome (classic)autosomal recessive · OMIM 222300submitted as: Wolfram syndrome 1
  • This rests on a single submitter (1★). Treat the conditions above as submitted, not as documented phenotypes.
  • Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient.
  • Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

Review status: 1★ single submitter. ClinVar "conditions" is the union of all submissions; 0–1★ entries are submitted conditions, not documented phenotypes.

Population frequency
Global (all ancestries)
AF 0.00027% · 4 / 1,459,140 alleles
Homozygotes
0
Highest-frequency population
European (non-Finnish) · AF 0.00036%

Highest in European (non-Finnish): AF 0.00036% (4 of 1,111,990 alleles), in line with the global figure.

No homozygotes reported in gnomAD v4. For a recessive allele this is expected and is not, on its own, evidence either way.

Ancestry groupAllele freq.AC / ANHom.Carrier est.
European (non-Finnish)0.00036%4 / 1,111,9900~1 in 139000

Source: gnomAD r4, retrieved 2026-08-21. Values are allele frequencies. The carrier estimate is derived from the allele frequency (Hardy-Weinberg, ~2·AF) and is an approximation, not a published figure — where a published carrier frequency exists it outranks this column and is cited on the card.

Therapeutic Strategy Handoff · prediction

Feed this card to Wolfram Intelligence

Download the W371* card below and upload it to Wolfram Intelligence to generate therapeutic-strategy proposals matched to this N1 nonsense variant and its domain context.

Full Variant Card

W371* — WFS1 Molecular Atlas Card

Variant type: Nonsense (premature stop codon) Position: 371 Wild-type residue: Tryptophan (W) Domain context (where the stop falls): Transmembrane helix 3


Schema category: N1 — NMD-targeted — null allele

Transcript degraded by NMD; no truncated protein produced. Therapeutic options: (a) translational readthrough drugs — Ataluren/PTC124, gentamicin-class aminoglycosides — may rescue partial readthrough; (b) gene therapy — allele replacement is the higher-yield long-term path. Pharmacological chaperones do not apply since no protein is made.


NMD prediction

  • Status: NMD-targeted
  • Confidence: high
  • Reasoning: Stop codon at position 371 is more than 50 nt upstream of the last exon-exon junction (~aa 413). The 50-nt rule predicts the transcript is degraded by nonsense-mediated decay. No truncated protein is produced; functionally a null allele.

Truncation analysis

  • Residues retained: 1 – 370 (41.6% of full-length protein)
  • Residues lost: 371 – 890 (58.4% of full-length protein)

Retained domains

  • N-terminal cytoplasmic (intrinsically disordered) (aa 1–310)
  • Transmembrane helix 1 (aa 311–331)
  • Cytoplasmic loop 1 (aa 332–340)
  • Transmembrane helix 2 (aa 341–361)
  • Lumenal loop 1 (aa 362–370)

Lost domains

  • Transmembrane helix 3 (aa 371–391)
  • Cytoplasmic loop 2 (aa 392–400)
  • Transmembrane helix 4 (aa 401–421)
  • Lumenal loop 2 (aa 422–431)
  • Transmembrane helix 5 (aa 432–452)
  • Cytoplasmic loop 3 (aa 453–461)
  • Transmembrane helix 6 (aa 462–482)
  • Lumenal loop 3 (aa 483–496)
  • Transmembrane helix 7 (aa 497–517)
  • Cytoplasmic loop 4 (aa 518–532)
  • Transmembrane helix 8 (aa 533–553)
  • Lumenal loop 4 (aa 554–573)
  • Transmembrane helix 9 (aa 574–594)
  • Cytoplasmic loop 5 / pre-lumenal (aa 595–599)
  • C-terminal ER-lumenal (calcium binding, calmodulin, chaperone) (aa 600–890)

Clinical evidence

Inheritance and scope

Pathogenic — for Wolfram syndrome (classic) (autosomal recessive, OMIM 222300)

ClinVar classifies this variant as Pathogenic for Wolfram syndrome (classic) (autosomal recessive, OMIM 222300). Classic Wolfram syndrome is recessive: a single copy does not produce it, and this classification says nothing about a carrier's own risk.

This rests on a single submitter (1★). Treat the conditions above as submitted, not as documented phenotypes. Phenotype scope is interpretation of submitted records. The computed values on this card (AlphaMissense, DynaMut2 ΔΔG, pLDDT) are measurements of the model, not of a patient. Presentation cannot be generalised from neighbouring variants: one nucleotide over can present very differently. Structural similarity supports a mechanistic hypothesis, never a phenotype claim.

  • Classification: Pathogenic
  • Review status: criteria provided, single submitter
  • Associated conditions: Wolfram syndrome 1
  • cDNA change: c.1112G>A
  • ClinVar accession: VCV001709531
  • Last evaluated: 2022/07/19 00:00
  • Submissions: 1

Population frequency

  • Frequency: Ultra-rare · AF 0.0003%
  • Allele count: 4 of 1,459,140 alleles (~729,570 individuals)
  • gnomAD variant ID: 4-6301248-G-A
  • Interpretation: Observed at very low frequency in gnomAD.

Source: gnomAD v4 joint exome + genome callset, cached locally. Frequency is population evidence only — it does not by itself establish or exclude pathogenicity.


Why this variant matters

This variant is biologically silent — the transcript is degraded before any truncated protein can be made. From a therapeutic standpoint, that simplifies the problem (one null allele) and points toward two specific paths: readthrough compounds that exploit the ribosome's natural ability to bypass premature stops, or gene-level replacement therapy. The atlas surfaces this clarity directly.


Card generated by wolfram-atlas-batch skill (v1) on 2026-07-31T21:00:57.251808Z. NMD rule and schema definitions: reference/nmd_rules.md, reference/card_schema_extension.md. WFS1 reference: UniProt O76024, AlphaFold model v6.